TABLE OF CONTENTS
1 INTRODUCTION 12
1.1 OBJECTIVES OF THE STUDY 12
1.2 MARKET DEFINITION 12
1.3 OVERVIEW OF THE SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET 12
1.4 CURRENCY AND PRICING 14
1.5 LIMITATIONS 14
1.6 MARKETS COVERED 14
2 MARKET SEGMENTATION 16
2.1 MARKETS COVERED 16
2.2 GEOGRAPHICAL SCOPE 17
2.3 YEARS CONSIDERED FOR THE STUDY 17
2.4 DBMR TRIPOD DATA VALIDATION MODEL 18
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 22
2.6 MULTIVARIATE MODELLING 23
2.7 MARKET APPLICATION COVERAGE GRID 24
2.8 PRODUCT LIFELINE CURVE 25
2.9 DBMR MARKET POSITION GRID 27
2.10 VENDOR SHARE ANALYSIS 28
2.11 SECONDARY SOURCES 29
2.12 ASSUMPTIONS 29
3 EXECUTIVE SUMMARY 30
4 PREMIUM INSIGHTS 33
4.1 PESTEL ANALYSIS 36
4.2 PORTERS FIVE FORCES 37
5 INDUSTRY INSIGHTS 38
5.1 PATENT ANALYSIS 38
5.2 DRUG TREATMENT RATE BY MATURED MARKETS 38
5.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATE 38
5.4 KEY PRICING STRATEGIES 39
6 REGULATORY GUIDELINES FOR IMMUNOHEMATOLOGY 41
6.1 REGULATIONS IN SAUDI ARABIA 41
6.2 REGULATIONS IN TURKEY 41
6.3 REGULATIONS IN EGYPT 42
7 MARKET OVERVIEW 43
7.1 DRIVERS 45
7.1.1 INCREASING DEMAND FOR BLOOD AND BLOOD PRODUCTS 45
7.1.2 TECHNOLOGICAL ADVANCEMENTS FOR THE DEVELOPMENT OF NEW PRODUCTS 45
7.1.3 INCREASING INCIDENCE OF TRAUMA AND IMMUNOHEMATOLOGICAL DISORDERS 45
7.2 RESTRAINTS 46
7.2.1 HIGH COST OF BLOOD TESTING AND TRANSFUSION 46
7.2.2 STRINGENT REGULATIONS FOR IMMUNOHEMATOLOGY TESTING IN SAUDI ARABIA, TURKEY, AND EGYPT 46
7.3 OPPORTUNITIES 47
7.3.1 RISING AWARENESS ABOUT BLOOD DONATION 47
7.3.2 RISING CASES OF BLOOD CANCER 47
7.4 CHALLENGES 48
7.4.1 RISK OF TRANSFUSION-TRANSMITTED INFECTIONS 48
7.4.2 LACK OF SKILLED PERSONNEL TO CARRY OUT IMMUNOHEMATOLOGY TESTING. 48
8 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET, BY PRODUCT TYPE 49
8.1 OVERVIEW 50
8.2 IMMUNOHEMATOLOGY ANALYZER 57
8.3 IMMUNOHEMATOLOGY REAGENT 57
9 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET, BY TECHNOLOGY 58
9.1 OVERVIEW 59
9.2 MICROPLATES 67
9.3 GEL CARDS 67
9.4 POLYMERASE CHAIN REACTION 67
9.5 ERYHTROCYTE-MAGNETIZED TECHNOLOGY (EMT) 67
9.6 OTHERS 68
10 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET, BY APPLICATION 69
10.1 OVERVIEW 70
10.2 BLOOD TYPING 77
10.3 ANTIBODY SCREENING 77
11 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET, BY END USER 78
11.1 OVERVIEW 79
11.2 BLOOD BANKS 86
11.3 HOSPITALS 86
11.4 DIAGNOSTIC AND REFERENCE LABORATORIES 86
11.5 ACADEMIC AND RESEARCH INSTITUTES 86
12 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET, BY DISTRIBUTION CHANNEL 87
12.1 OVERVIEW 88
12.2 DIRECT SALES 95
12.3 THIRD PARTY DISTRIBUTION 95
12.4 RETAIL SALES 95
13 SAUDI ARABIA, TURKEY, AND EGYPT IMMUNOHEMATOLOGY MARKET, COMPANY LANDSCAPE 96
13.1 COMPANY SHARE ANALYSIS: TURKEY 96
13.2 COMPANY SHARE ANALYSIS: SAUDI ARABIA 97
13.3 COMPANY SHARE ANALYSIS: EGYPT 98
14 SWOT ANALYSIS 99
15 COMPANY PROFILE 100
15.1 ABBOTT 100
15.1.1 COMPANY SNAPSHOT 100
15.1.2 REVENUE ANALYSIS 100
15.1.3 PRODUCT PORTFOLIO 101
15.1.4 RECENT DEVELOPMENT 101
15.2 ORTHO CLINICAL DIAGNOSTICS 102
15.2.1 COMPANY SNAPSHOT 102
15.2.2 REVENUE ANALYSIS 102
15.2.3 PRODUCT PORTFOLIO 103
15.2.4 RECENT DEVELOPMENTS 103
15.3 SIEMENS HEALTHINEERS AG 104
15.3.1 COMPANY SNAPSHOT 104
15.3.2 REVENUE ANALYSIS 104
15.3.3 PRODUCT PORTFOLIO 105
15.3.4 RECENT DEVELOPMENTS 105
15.4 BECKMAN COULTER, INC. 106
15.4.1 COMPANY SNAPSHOT 106
15.4.2 REVNUE ANALYSIS 106
15.4.3 PRODUCT PORTFOLIO 107
15.4.4 RECENT DEVELOPMENT 107
15.5 HORIBA 108
15.5.1 COMPANY SNAPSHOT 108
15.5.2 REVENUE ANALYSIS 108
15.5.3 PRODUCT PORTFOLIO 109
15.5.4 RECENT DEVELOPMENTS 109
15.6 BIO RAD LABORATORIES, INC. 110
15.6.1 COMPANY SNAPSHOT 110
15.6.2 REVENUE ANALYSIS 110
15.6.3 PRODUCT PORTFOLIO 111
15.6.4 RECENT DEVELOPMENTS 111
15.7 IMMUCOR, INC. 112
15.7.1 COMPANY SNAPSHOT 112
15.7.2 PRODUCT PORTFOLIO 112
15.7.3 RECENT DEVELOPMENTS 112
15.8 MERCK KGAA 113
15.8.1 COMPANY SNAPSHOT 113
15.8.2 REVENUE ANALYSIS 113
15.8.3 PRODUCT PORTFOLIO 114
15.8.4 RECENT DEVELOPMENTS 114
15.9 THERMO FISCHER SCIENTIFIC INC. 115
15.9.1 COMPANY SNAPSHOT 115
15.9.2 REVENUE ANALYSIS 115
15.9.3 PRODUCT PORTFOLIO 116
15.9.4 RECENT DEVELOPMENTS 116
16 QUESTIONNAIRE 117
17 RELATED REPORTS 120

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.